Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?

Anti‐PD‐1/PD‐L1 agents play a crucial part in the treatment of non‐small cell cancer (NSCLC) demonstrating improved overall response rate (ORR) and overall survival (OS). Recent studies evaluating combination treatment with anti‐PD‐1 and anti‐CTLA‐4 suggests improved outcome but also increased toxic...

Full description

Bibliographic Details
Main Authors:	Michal Sternschuss, Nir Peled, Aaron M. Allen, Elizabeth Dudnik, Ofer Rotem, Noga Kurman, Omer Gal, Hiba Reches, Alona Zer
Format:	Article
Language:	English
Published:	Wiley 2020-08-01
Series:	Thoracic Cancer
Subjects:	Immune‐related adverse events ipilimumab nivolumab NSCLC
Online Access:	https://doi.org/10.1111/1759-7714.13502

Similar Items

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
by: Taylor E. Woo, et al.
Published: (2023-09-01)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
by: Valerie Glutsch, et al.
Published: (2019-07-01)

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
by: Yuanquan Yang, et al.
Published: (2022-04-01)

Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
by: Maggie Zhou, et al.
Published: (2021-03-01)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
by: Takeshi Fukumoto, et al.
Published: (2022-08-01)

CTLA-4 and PD-1 pathway Blockade : Combinations in the Clinic
by: Margaret Kathleen Callahan, et al.
Published: (2015-01-01)

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
by: Taku Fujimura, et al.
Published: (2018-01-01)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022-08-01)

Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
by: Taku Fujimura, et al.
Published: (2020-03-01)

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
by: Walid Shalata, et al.
Published: (2023-08-01)

Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature
by: Jan Skacel, et al.
Published: (2023-12-01)

Prospects of application of inhibitors of PD-1/PD-L1 checkpoints in malignant tumors of the stomach and esophagogastric junction
by: D. D. Sakaeva, et al.
Published: (2020-12-01)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
by: Carl Morrison, et al.
Published: (2018-05-01)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
by: M. N. Khagazheeva, et al.
Published: (2022-06-01)

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
by: Vincenzo Quagliariello, et al.
Published: (2020-10-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
by: Lucía Vázquez-Montero, et al.
Published: (2023-06-01)

Challenges with anti-PD1 agents in brain metastases management of NSCLC patients: a case report
by: Alessandro Russo, et al.
Published: (2018-06-01)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023-03-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
by: Mikako Nakamura, et al.
Published: (2023-02-01)

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
by: Rebecca Charles, et al.
Published: (2023-09-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab
by: Shelby L Kubicki, et al.
Published: (2018-10-01)

Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004)
by: Tsuchiya-Kawano Y, et al.
Published: (2021-11-01)

Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review
by: Makoto Fujiwara, et al.
Published: (2023-12-01)

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
by: Yixin Zhou, et al.
Published: (2020-03-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
by: Remon J, et al.
Published: (2019-05-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
by: Aoi Motonaga, et al.
Published: (2021-09-01)

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial
by: Jeffrey M. Clarke, MD, et al.
Published: (2022-06-01)

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
by: Omid Kooshkaki, et al.
Published: (2020-06-01)

Results of combined nivolumab and ipilimumab therapy in patients with cancer
by: M. A. Lyadova, et al.
Published: (2021-12-01)

Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
by: Katrin Goepfert, et al.
Published: (2019-05-01)

Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
by: Hiroshi Sawayama, et al.
Published: (2022-12-01)

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
by: Yoshiyuki Nakamura, et al.
Published: (2021-02-01)

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
by: Julia Katharina Schwarze, et al.
Published: (2022-01-01)

PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma
by: Maria Davern, et al.
Published: (2023-06-01)

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
by: Hisato Kawakami, et al.
Published: (2021-02-01)